Don Tracy, Associate Editor

The draft assessment finds that the popular weight loss drugs are costly but worth the price tag, while also urging for broader coverage and policy solutions.

Ron Lanton, partner, Lanton Law, explains that declining public trust and political support for vaccines could force pharmaceutical companies to rethink regulatory strategies and investment priorities in biologics and vaccine development.

Ron Lanton, Partner, Lanton Law, warns that shifting federal policies and ongoing lawsuits could create compliance challenges and operational risks that pharmaceutical supply chain leaders must closely monitor.

Agreement allows educational institutions to access cold chain packaging solutions without the typical request for proposal process, supporting research, lab operations, and healthcare training.

Per the deal, Thermo Fisher will acquire Sanofi’s sterile drug product manufacturing facility in Ridgefield, NJ, to support production of Sanofi therapies and expand capacity for US-based pharma and biotech manufacturing.

Bruce Leuchter, CEO, Neurvati, explains how industry and advocacy groups can work together to ensure patient and caregiver perspectives continue to inform regulatory decisions—even without a formal public engagement pathway.

Bruce Leuchter, CEO, Neurvati, explains why aligning drug development with patient-reported outcomes is key to demonstrating value and achieving payer alignment in the rare disease space.

Bruce Leuchter, CEO, Neurvati, discusses why patient engagement is essential to understanding rare diseases and driving the development of breakthrough therapies.

Bruce Leuchter, CEO, Neurvati, discusses the vital role of public participation in healthcare policy, highlighting how patient and caregiver insights shape drug development, regulatory decisions, and payer considerations in rare diseases.